Marksans Pharma Q1FY27 Consolidated Revenue ₹8,407 Crore, Profit ₹1,594 Crore
Marksans Pharma reported Q1FY27 consolidated revenue of ₹8,407.96 crore and profit after tax of ₹1,594.07 crore. Standalone profit after tax was ₹690.37 crore. The company acquired QUiniQ B.V. for EUR 7.50 million and ABCnow GmbH for EUR 1.10 million. Stock options were granted to employees.
The financial results show robust performance, and the strategic acquisitions are significant corporate actions that are likely to have a substantial impact on the company's future growth and market position.
The company reported strong financial results with increased revenue and profit on a consolidated basis. The acquisitions of QUiniQ B.V. and ABCnow GmbH are strategic moves that are expected to enhance the company's market presence and capabilities.
Marksans Pharma Limited announced its unaudited financial results for the quarter ended June 30, 2026. The Board of Directors approved the consolidated and standalone financial results on August 12, 2026. The meeting commenced at 10:50 a.m. and concluded at 12:10 p.m.
On a consolidated basis, the company reported a total income of ₹8,662.00 crore, with revenue from operations at ₹8,407.96 crore. Profit after tax for the quarter stood at ₹1,594.07 crore. Total comprehensive income attributable to owners of the company was ₹1,738.57 crore.
On a standalone basis, total income was ₹3,386.57 crore, and profit after tax was ₹690.37 crore. Earnings per share (basic and diluted) for the consolidated results were ₹3.47, and for standalone results were ₹1.52.
The company also disclosed that its statutory auditors, MSKA & Associates LLP, have submitted their Limited Review Reports with an unmodified opinion for both consolidated and standalone results.
Key developments during the quarter include the acquisition of 100% share capital of QUiniQ B.V. in the Netherlands for EUR 7.50 million. Subsequent to the quarter, Marksans Pharma completed the acquisition of 100% of ABCnow GmbH in Germany for EUR 1.10 million.
Additionally, 300,000 stock options were granted under the Marksans Employees Stock Option Scheme 2024 to eligible employees.
What to do with a filing like this
Marksans Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Marksans Pharma Limited. Read the original for the full detail.